<DOC>
	<DOC>NCT00886574</DOC>
	<brief_summary>This multi-center, randomized controlled study aims to evaluate the efficacy of Cilostazol versus Aspirin for primary prevention of atherosclerotic events with Korean type 2 Diabetes Mellitus (DM) patients.</brief_summary>
	<brief_title>Cilostazol Versus Aspirin for Primary Prevention of Atherosclerotic Events</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Cilostazol</mesh_term>
	<criteria>1. Type 2 diabetes mellitus with high risk of macrovascular complications; high risk is one or more as follows: Hypertension (â‰§ 140/90 or antihypertensive therapy) Hypercholesterolemia (LDLC &gt; 130 mg/dL or antihyperlipidemic therapy) TG &gt; 200 mg/dL Non proliferative retinopathy or macular edema Microalbuminuria or macroalbuminuria Smoker 2. Patients on no anti PLT drug history 3. Patients who are agree with this research 1. Type 1 diabetes mellitus 2. Macrovascular complication history 3. Uncontrolled hypertension, unstable angina history 4. Congestive heart failure 5. Bleeding tendency 6. Chronic liver disease (ALT &gt; 100 or AST &gt; 100) or Chronic renal disease creatinine &gt; 3.0 mg/dl) 7. Anemia (hemoglobin &lt; 10 mg/dl) or thrombocytopenia (platelet count less than 100,000/mm3) 8. Pregnant or lactation women 9. Plan to be revascularized in 4 weeks 10. Plan to go to surgery or invasive intervention in 4 weeks 11. Plan to need to admission for acute cardiovascular disease in 4 weeks 12. Contraindication of this medication 13. Other antiPLT drug therapy</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Cilostazol versus Aspirin</keyword>
	<keyword>Anti-PLT drug</keyword>
	<keyword>Primary Prevention of Atherosclerotic Events</keyword>
	<keyword>Type 2 DM</keyword>
	<keyword>Intima media thickness (IMT)</keyword>
</DOC>